The authors examined cost-effectiveness in the National Lung Screening Trial (NLST), examining incremental cost-effectiveness ratio (ICER) and quality-adjusted life years (QALYs) associated with low dose CT screening. The ICER was $52,000 per life-year gained and the $81,000 per QALY gained. These values were very sensitive to variations in the screening algorithms.
You are here:
Cost-Effectiveness of CT Screening in the National Lung Screening Trial
Submitted by: Mark Ferguson
Source: New England Journal of Medicine
Keywords:
Author(s): William C. Black, Ilana F. Gareen, Samir S. Soneji, JoRean D. Sicks, Emmett B. Keeler, Denise R. Aberle, Arash Naeim, Timothy R. Church, Gerard A. Silvestri, Jeremy Gorelick, and Constantine Gatsonis for the National Lung Screening Trial Research Team
